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Introduction: This was a descriptive non-interventional study in HIV-1-infected patients treated with DRV/r conducted in the
clinical setting, with a single-arm prospective design. The primary objective was to collect data on utilization of darunavir/
ritonavir (DRV/r) under the conditions described in the marketing authorization. Efficacy (measured as viral load [VL] B50
copies/mL and CD4 cell count) was evaluated for DRV/r in combination with other antiretroviral (ARV) agents in routine
clinical practice in Italy.
Materials and Methods: Here we describe an analysis of effectiveness and durability data from two cohorts of DRV/r-
experienced patients with HIV-1 infection, already receiving DRV/r according to usual clinical practice, collected prospectively
from June 2009 to December 2012: Cohort 1, data from patients from the DRV/r Early Access Program (TMC114-C226 study;
N235 patients) and Cohort 2, a separate cohort of ARV-DRV/r-experienced patients (N407 patients), treated with DRV/r in
the market. Patient characteristics are shown in Table 1.
Published 2 November 2014
Copyright: – 2014 Antinori A et al; licensee International AIDS Society. This is an Open Access article distributed under the terms of the Creative Commons
Attribution 3.0 Unported (CC BY 3.0) License (http://creativecommons.org/licenses/by/3.0/), which permits unrestricted use, distribution, and reproduction in any
medium, provided the original work is properly cited.
Table 1. Patient characteristics
Baseline characteristics Parameters Cohort 1 (N235) N, (%) Cohort 2 (N407) N, (%)
Age, yrs, mean9SD 49.397.1 46.699.4
Female, n (%) 45 (19.1) 107 (26.3)
VL (HIV-RNA) B50 copies/mL, n (%)a at study enrolment 192 (85) 298 (74.9)
CD4B100 cells/mL, n (%)b at study enrolment 7 (3.1) 25 (6.2)
Duration of HIV infection, n (%)
01 year 0 53 (13.0)
110 years 6 (2.6) 82 (20.1)
1015 years 62 (26.4) 66 (16.2)
1520 years 89 (37.9) 85 (20.9)
20 years 76 (32.3) 110 (27.0)
NA 2 (0.9) 11 (2.7)
CDC clinical stage, n (%)
A 30 (12.8) 139 (34.2)
B 80 (34.0) 121 (29.7)
C 125 (53.2) 147 (36.1)
Time since first DRV dose (days), at study enrolment  mean9SD 12429208 5019402
Study Duration, days  mean9SD 8129286 5839188
DRV dose at study entry, mg/day, n (%)
1200 232 262
800 3 145
aVL data only available in 226 Cohort 1 and 398 Cohort 2 patients. bCD4 data only available in 226 Cohort 1 and 403 Cohort 2 patients.
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Results: The median length of DRV/r exposure during the study was 925 days (interquartile range [IQR] 6921006) in Cohort 1,
and 581 (IQR 508734) days in Cohort 2. Of those patients that completed the study, 94% and 87% of patients were virologically
suppressed in Cohort 1 and 2, respectively, at last study visit (LSV). As expected, the virological suppression rate was higher in
patients with baseline VL B50 copies/mL (Table 2). Mean CD4 cell counts improved from baseline to LSV in both cohorts
(Cohort 1:54 cells/mL [95% CI 31, 77] and Cohort 2:59 cells/mL [95% CI 44, 73]). High persistence rates were seen in both
cohorts, with 75.3% of patients in Cohort 1 and 82.6% in Cohort 2 remaining on treatment at LSV; very few patients
discontinued due to virologic failure (Table 1). Other reasons for study discontinuation are shown in Table1. Very few patients
changed DRV/r dosing during the study, 15 from 1200 to 800 mg o.d.
Conclusions: In patients already treated with DRV/r, DRV/r-based ARV treatment provided effective viral suppression with long-
lasting durability, low virological response failure, low discontinuation rates and good tolerability. These data confirm DRV/r to
be an effective treatment choice in previously treated patients.
Table 2. Patient characteristics
Virological EfficacyParameters Cohort 1 (N235) N, (%) Cohort 2 (N407) N, (%)
LSV VL [HIV-RNA B50 copies/mL], n (%)a
All 203 (88.6) 331 (83.6)
BL VL B50 copies/mL 177 (94.1) 263 (89.2)
BL VL ]50 copies/mL 19 (59.4) 60 (65.2)
No values for BL VL 7 (77.8) 8 (88.9)
Total discontinuations at LSV, n (%) 56 (24.7) 71 (17.4)
Reasons for discontinuation, n (%)
Insufficient virological response 8 (3.4) 4 (1.0)
Death 10 (4.3) 9 (2.2)
Study emergent adverse event 3 (1.3) 9 (2.2)
Other study emergent medical reason 0 1 (0.2)
Lack of compliance 4 (1.7) 8 (2.0)
Lost to follow-up 23 (9.8) 18 (4.4)
Other 9 (3.8) 20 (4.9)
aVL data only available in 226 Cohort 1 and 398 Cohort 2 patients.
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